Drug Discovery

Today, scientists still do not know the cause of Alzheimer’s disease (AD), yet decades of research advancements give hope to the possibility of slowing down early-onset of AD. Benfotiamine, a therapeutic drug that raises blood vitamin B1, levels very high, was recently tested as a pilot clinical study conducted by the Gibson Lab at the Burke Neurological Institute.

A small exploratory clinical trial conducted by Dr. Gary E. Gibson’s laboratory at the Burke Neurological Institute in collaboration with physicians at the Burke Rehabilitation Hospital, suggests that Benfotiamine is safe and potentially efficacious in improving cognitive outcomes among people living with Mild Cognitive Impairment and mild Alzheimer’s disease (AD).